Thermo Fisher Scientific Showcases at CPHI Frankfurt 2022
Thermo Fisher Experts will demonstrate its various capabilities at CPHI Frankfurt 2022.
Thermo Fisher Scientific will showcase its expertise, innovations, and capabilities to help pharmaceutical and emerging biotech companies via various modalities and platforms, including cell and gene therapies, oral solids, steriles, and biologics at CPHI Frankfurt 2022. Thermo Fisher experts will be available at CPHI Frankfurt 2022, Nov. 1-3, 2022, Booth #90J10, Hall 9.
"As pharma and biotechs look to transform molecules to medicines, they are looking for integrated solutions that connect the entire value chain from early development and clinical trials to scalable manufacturing and integrated sourcing," said Leon Wyszkowski, president of commercial operations, pharma services, Thermo Fisher Scientific, in a company press release. “This week, we will demonstrate our deep expertise across a range of topics — from clinical research and advanced therapies to digital technologies — to help our customers accelerate their innovation and speed the delivery of breakthrough medicines and therapies to patients.”
For more about Thermo Fisher sessions and activities at CPHl Frankfurt, visit this page.
Source: Thermo Fisher Scientific
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
